Skip to main content
SpringerLink
Log in

Genetisch stratifizierte Darmkrebstherapie

Von der Indikation für chirurgische Behandlung bis zur Systemtherapie

  • Topic_Darmkrebstherapie
  • Published:
best practice onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Kirchberg J, Weitz J (2014) Chancen und Risiken präventiver Operationen der viszeralen Organe. In: Hoefert H-W, Klotter C (Hrsg) Krankheitsprävention in der Kontroverse. Pabst, Lengerich, S 404

    Google Scholar 

  2. Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116:1453–1456

    Article  CAS  PubMed  Google Scholar 

  3. Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Neumann JHL, Kirchner T (2014) Colorectal carcinoma in consideration of the new German S3 gui-deline 2013. Pathol 35:615–621 (quiz 622-623)

    Article  CAS  Google Scholar 

  5. Lynch HT (1996) Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers Dis Colon Rectum 39:109–110

    Article  CAS  PubMed  Google Scholar 

  6. Bülow S (1986) Clinical features in familial polyposis coli. Results of the Danish Polyposis Register. Dis Colon Rectum 29:102–107

    Article  PubMed  Google Scholar 

  7. Foulkes WD (1995) A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome. QJM 88:853–863

    CAS  PubMed  Google Scholar 

  8. Bülow S (2003) Results of national registration of familial adenomatous polyposis. Gut 52:742–746

    Article  PubMed Central  PubMed  Google Scholar 

  9. Funkhouser WK, Lubin IM, Monzon FA et al (2012) Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn 14:91–103

    Article  CAS  PubMed  Google Scholar 

  10. Bosman F (2010) WHO classification of tumours of the digestive system. IARC, Lyon

    Google Scholar 

  11. Pox C, Aretz S, Bischoff SC et al (2013) S3-guideline colorectal cancer version 1.0. Z Gastroenterol 51:753–854

    Article  CAS  PubMed  Google Scholar 

  12. Goel A, Nagasaka T, Hamelin R, Boland CR (2010) An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS One 5:e9393

    Article  PubMed Central  PubMed  Google Scholar 

  13. Sargent DJ, Marsoni S, Monges G et al (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219–3226

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Leitlinienprogramm Onkologie (2013) S3-Leitlinie Kolorektales Karzinom. http://www.dgvs.de/file-admin/user_upload/Leitlinien/kolorektalesKarzinom/LL_KRK_Kurzfassung_OL.pdf

  15. Kartheuser AH, Parc R, Penna CP et al (1996) Ileal pouch-anal anastomosis as the first choice operation in patients with familial adenomatous polyposis: a ten-year experience. Surgery 119:615–623

    Article  CAS  PubMed  Google Scholar 

  16. Duijvendijk P van, Slors JF, Taat CW et al (1999) Functional outcome after colectomy and ileorectal anastomosis compared with proctocolectomy and ileal pouch-anal anastomosis in familial adenomatous polyposis. Ann Surg 230:648–654

    Article  PubMed Central  PubMed  Google Scholar 

  17. Cosse JJ de, Bülow S, Neale K et al (1992) Rectal cancer risk in patients treated for familial ade-nomatous polyposis. The Leeds Castle Polyposis Group. Br J Surg 79:1372–1375

    Article  PubMed  Google Scholar 

  18. Schiessling S, Leowardi C, Kienle P et al (2013) Laparoscopic versus conventional ileoanal pouch procedure in patients undergoing elective restorative proctocolectomy (LapConPouch Trial) - a randomized controlled trial. Langenbecks Arch Surg 398:807–816

    Article  PubMed  Google Scholar 

  19. Vos tot Nederveen Cappel WH de, Nagengast FM, Griffioen G et al (2002) Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 45:1588–1594

    Article  PubMed  Google Scholar 

  20. Järvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829–834

    Article  PubMed  Google Scholar 

  21. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9–S15

    Article  CAS  PubMed  Google Scholar 

  22. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  CAS  PubMed  Google Scholar 

  23. Karapetis CS, et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765

    Article  CAS  PubMed  Google Scholar 

  24. Van Cutsem E, Köhne C-H, Láng I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019

    Article  PubMed  Google Scholar 

  25. Van Cutsem E, Lenz H-J, Köhne C-H et al (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and ras mutations in colorectal cancer. J Clin Oncol (Epub ahead of print). DOI 10.1200/JCO.2014.59.4812

    Google Scholar 

  26. Douillard J-Y, Oliner KS, Siena S et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034

    Article  CAS  PubMed  Google Scholar 

  27. Bokemeyer C, Van Cutsem E, Rougier P et al (2012) Addition of cetuximab to chemotherapy as first-li-ne treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48:1466–1475

    Article  CAS  PubMed  Google Scholar 

  28. Ogino S, Shima K, Meyerhardt JA et al (2012) Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 18:890–900

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitu-mumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705–5712

    Article  PubMed  Google Scholar 

  30. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leu-covorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  CAS  PubMed  Google Scholar 

  31. Kabbinavar FF, Hambleton J, Mass RD et al (2005) Combined analysis of efficacy: the addition of be-vacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706–3712

    Article  CAS  PubMed  Google Scholar 

  32. Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499–3506

    Article  PubMed  Google Scholar 

  33. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544

    Article  CAS  PubMed  Google Scholar 

  34. Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29–37

    Article  CAS  PubMed  Google Scholar 

  35. Khattak MA, Martin H, Davidson A, Phillips M (2015) Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. Clin Colorectal Cancer (Epub ahead of print). DOI 10.1016/j.clcc.2014.12.011

    Google Scholar 

  36. Gray RG, Quirke P, Handley K et al (2011) Validation study of a quantitative multigene reverse tran-scriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 29:4611–4619

    Article  PubMed  Google Scholar 

  37. Venook AP, Niedzwiecki D, Lopatin M et al (2013) Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol 31:1775–1781

    Article  PubMed Central  PubMed  Google Scholar 

  38. Vauthey J-N, Zimmitti G, Kopetz SE et al (2013) RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 258:619–626 (discussion 626-627)

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Viszeral-, Thorax- und Gefäßchirurgie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Deutschland

    J. Kirchberg, J. Fritzmann & J. Weitz

  2. Institut für Pathologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Deutschland

    D. Aust

  3. Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Deutschland

    G. Folprecht

  4. Klinik und Poliklinik für Viszeral-, Thorax-und Gefäßchirurgie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland

    J. Kirchberg

Authors
  1. J. Kirchberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Aust
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Fritzmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Folprecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Weitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Kirchberg.

Additional information

Interessenkonflikt

J. Kirchberg, D. Aust, J. Fritzmann, G. Folprecht und J. Weitz geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kirchberg, J., Aust, D., Fritzmann, J. et al. Genetisch stratifizierte Darmkrebstherapie. best practice onkologie 10, 26–32 (2015). https://doi.org/10.1007/s11654-015-0244-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-015-0244-z

Search

Navigation